インスリン製剤の世界市場レポート 2025年

インスリン製剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.7％で464億7,000万米ドルに成長します。予測期間の成長は、疾病負担の増加、政府のイニシアティブ、研究開発および共同研究の増加に起因しています。予測期間の主な動向には、新製品を発売して製品ラインアップを増やすこと、M&Aを通じて製品ポートフォリオと事業を拡大すること、戦略的パートナーシップを採用して製品ラインアップの充実を図ること、新しいインスリン送達方法の開発に向けた研究開発投資を拡大すること、先進的ソリューションに投資して研究開発コストを削減し開発期間を短縮することなどが含まれます。

長時間労働、身体活動の低下、不健康な食習慣など、ライフスタイルの変化に伴う糖尿病有病率の増加が、予測期間における糖尿病治療薬の需要を押し上げると予想されます。座りがちな生活習慣は糖尿病の発症率上昇につながり、肥満に悩む人は2型糖尿病の発症リスクが最大80倍上昇します。世界保健機関（WHO）の動向では、2030年までに英国では男性の74％、女性の64％が太りすぎになると予想されており、懸念すべき傾向を示しています。このような糖尿病患者の急増は、糖尿病治療薬市場を促進すると思われます。

インスリン製剤市場は、糖尿病の危険因子として知られる肥満の有病率が上昇していることから、成長が見込まれています。健康に悪影響を及ぼす過剰な体脂肪を特徴とする肥満は、糖尿病開発と密接な関係があります。肥満の文脈で使用されるインスリン製剤は体重増加を助長し、肥満問題を悪化させる可能性があります。例えばイングランドでは、政府デジタルサービスの予測によると、2021年から2022年の間に18歳以上の肥満が25.2％増加するとされています。肥満率の上昇は、インスリン製剤市場の成長にとって重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界インスリン製剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のインスリン製剤市場：成長率分析
• 世界のインスリン製剤市場の実績：規模と成長, 2019-2024
• 世界のインスリン製剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界インスリン製剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のインスリン製剤市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 基礎インスリンまたは持続性インスリン
• ボーラスまたは速効型インスリン
• プレミックス
• 中間および短時間作用型インスリン
• 世界のインスリン製剤市場ソースタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリンアナログ
• ヒトインスリン
• 世界のインスリン製剤市場薬物分類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド医薬品
• ジェネリック医薬品
• 世界のインスリン製剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2型糖尿病
• 1型糖尿病
• 妊娠糖尿病
• 世界のインスリン製剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン
• 世界のインスリン製剤市場、基礎インスリンまたは持続性インスリンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリングラルギン
• インスリンデテミル
• インスリンデグルデク
• 世界のインスリン製剤市場、ボーラスインスリンまたは速効型インスリンの種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリンアスパルト
• インスリンリスプロ
• インスリングルリジン
• 世界のインスリン製剤市場、プレミックスのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 二相性インスリン製剤
• 持続型インスリンと速効型インスリンの混合製剤
• 世界のインスリン製剤市場、中間型および短時間作用型インスリンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリンNPH（中性プロタミンハゲドン）
• レギュラーインスリン（速効型）

第7章 地域別・国別分析

• 世界のインスリン製剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のインスリン製剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インスリン製剤市場：競合情勢
• インスリン製剤市場：企業プロファイル
  • Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly And Company Overview, Products and Services, Strategy and Financial Analysis
  • Biocon Ltd Overview, Products and Services, Strategy and Financial Analysis
  • and Gan & Lee Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bioton
• Wockhardt Ltd
• Julphar
• Tonghua Dongbao Pharmaceutical
• AstraZeneca
• NIPRO
• Olympus Medical Systems
• Hitachi Medico
• Nihon Kohden
• Fukuda Denshi
• Emperra GmbH E-Health Technologies
• DIABNEXT
• Berlin-Chemie AG
• Ypsomed Holding AG
• Patients Pending Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インスリン製剤市場2029：新たな機会を提供する国
• インスリン製剤市場2029：新たな機会を提供するセグメント
• インスリン製剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Insulin drugs are medications prescribed for the treatment of diabetes, encompassing both type 1 diabetes and type 2 diabetes mellitus. These drugs come in various types, preparations, and dosage amounts. Insulin, a hormone naturally produced in the body, plays a crucial role in facilitating the uptake of glucose (sugar) by cells throughout the body, converting it into a form usable for energy.

The primary product types of insulin drugs include basal or long-acting insulins, bolus or fast-acting insulins, pre-mixed insulins, and intermediate and short-acting insulins. Basal or long-acting insulins are utilized in diabetes management to provide a slow, steady release of insulin throughout the day and night. Insulin source types include insulin analogs and human insulin, while drugs are categorized into branded and generic drugs, distributed through hospital pharmacies, retail pharmacies, and online platforms. The various applications of insulin drugs encompass type II diabetes, type I diabetes, and gestational diabetes.

The insulin drugs market research report is one of a series of new reports from The Business Research Company that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry. This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insulin drugs market size has grown strongly in recent years. It will grow from $35 billion in 2024 to $37.29 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increase in diabetes prevalence, emerging markets growth, increased geriatric population and growth in insulin analogues.

The insulin drugs market size is expected to see strong growth in the next few years. It will grow to $46.47 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to the increase in disease burden, government initiatives and increase in R&D and collaborations. Major trends in the forecast period include launching new products to increase their product offerings, expanding product portfolio and business through mergers and acquisitions, adopting strategic partnerships to promote product offerings, investing more in research and development towards developing new insulin delivery methods, investing in advanced solutions to reduce R&D costs and save development time.

The increasing prevalence of diabetes, driven by changing lifestyles marked by long working hours, reduced physical activity, and unhealthy eating habits, is anticipated to boost the demand for diabetes drugs in the forecast period. Sedentary lifestyles have been linked to a higher incidence of diabetes, and individuals suffering from obesity face up to an 80-fold increased risk of developing type 2 diabetes. Projections from the World Health Organization (WHO) indicate a concerning trend, with an expected 74% of men and 64% of women in the UK being overweight by 2030. This surge in diabetes cases is likely to propel the diabetes therapies market.

The insulin drugs market is poised for growth due to the rising prevalence of obesity, a known risk factor for diabetes. Obesity, characterized by excess body fat adversely affecting health, is closely linked to diabetes development. Insulin drugs, used in the context of obesity, can contribute to weight gain, exacerbating the obesity issue. In England, for instance, projections from the Government Digital Service indicate a 25.2% increase in obesity among individuals aged 18 and older in the period 2021-2022. The escalating rates of obesity are a key driver for the growth of the insulin drugs market.

A discernible trend in the insulin market is the increasing number of mergers and acquisitions focused on developing new formulations. Companies are actively investing in innovative medicines for diabetes treatment. Researchers at Lund University Diabetes Centre utilized CRISPR, a genome modification tool, to turn off genes responsible for diabetes, resulting in increased insulin production and decreased beta cell death. Novo Nordisk has developed a diabetes pill based on glucagon-such as peptide-1 (GLP-1s) that stimulates insulin production, anticipating significant annual sales.

Major companies in the insulin drugs market are emphasizing product innovation, exemplified by the introduction of the triple fixed-dose combination (FDC) of teneligliptin with pioglitazone and metformin. Glenmark Pharmaceuticals Limited, an Indian pharmaceutical company, launched Zita-PioMet, a triple FDC for treating type 2 diabetes and high insulin resistance. This innovation aims to improve glycemic control in adults with uncontrolled diabetes despite other treatments.

In March 2024, Eris Lifesciences Ltd., a pharmaceutical company based in India, acquired Biocon Biologics for $169 million. Through this acquisition, Eris intends to broaden its portfolio by integrating Biocon Biologics's expertise in the production of insulin drugs. Biocon Biologics Limited is also an India-based company specializing in the manufacture of insulin drugs.

Major companies operating in the insulin drugs market include Novo Nordisk, Sanofi S.A., Eli Lilly And Company, Biocon Ltd, and Gan & Lee Pharmaceuticals, Bioton, Wockhardt Ltd, Julphar, Tonghua Dongbao Pharmaceutical, AstraZeneca, NIPRO, Olympus Medical Systems, Hitachi Medico, Nihon Kohden, Fukuda Denshi, Emperra GmbH E-Health Technologies, DIABNEXT(TM), Berlin-Chemie AG, Ypsomed Holding AG, Patients Pending Ltd, Dexcom, Johnson and Johnson, Medtronic, Abbott Laboratories, Acon Laboratories, Tandem Diabetes Care, Inc., Becton, Dickinson, Insulet Corporation, AJA Pharma, SEDICO Pharmaceutical Company, Pfizer

North America was the largest region in the insulin drugs market in 2024. Middle East is expected to be the largest growing region in the global insulin drugs market share during the forecast period. The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the insulin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The insulin drugs market consists of sales of rapid-acting insulin, short-acting insulin, and mixed insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Insulin Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insulin drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for insulin drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The insulin drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Basal Or Long-Acting Insulins, Bolus Or Fast-Acting Insulins, Pre-Mixed, And Intermediate And Short Acting Insulins
• 2) By Source Type: Insulin Analogs, And Human Insulin
• 4) By Drug Classification: Branded Drugs, And Generic Drugs
• 3) By Application: Type 2 Diabetes, Type 1 Diabetes, And Gestational Diabetes
• 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, And Online
• Subsegments:
• 1) By Basal Or Long-Acting Insulins: Insulin Glargine; Insulin Detemir; Insulin Degludec
• 2) By Bolus Or Fast-Acting Insulins: Insulin Aspart; Insulin Lispro; Insulin Glulisine
• 3) By Pre-Mixed: Biphasic Insulin Formulations; Pre-Mixed Combinations Of Long-Acting And Fast-Acting Insulins
• 4) By Intermediate And Short-Acting Insulins: Insulin NPH (Neutral Protamine Hagedorn); Regular Insulin (Short-Acting)
• Companies Mentioned: Novo Nordisk; Sanofi S.A.; Eli Lilly And Company; Biocon Ltd; and Gan & Lee Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Insulin Drugs Market Characteristics

3. Insulin Drugs Market Trends And Strategies

4. Insulin Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Insulin Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Insulin Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Insulin Drugs Market Growth Rate Analysis
• 5.4. Global Insulin Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Insulin Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Insulin Drugs Total Addressable Market (TAM)

6. Insulin Drugs Market Segmentation

• 6.1. Global Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Basal Or Long-Acting Insulins
• Bolus Or Fast-Acting Insulins
• Pre-Mixed
• Intermediate And Short Acting Insulins
• 6.2. Global Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Analogs
• Human Insulin
• 6.3. Global Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Drugs
• Generic Drugs
• 6.4. Global Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2 Diabetes
• Type 1 Diabetes
• Gestational Diabetes
• 6.5. Global Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online
• 6.6. Global Insulin Drugs Market, Sub-Segmentation Of Basal Or Long-Acting Insulins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Glargine
• Insulin Detemir
• Insulin Degludec
• 6.7. Global Insulin Drugs Market, Sub-Segmentation Of Bolus Or Fast-Acting Insulins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Aspart
• Insulin Lispro
• Insulin Glulisine
• 6.8. Global Insulin Drugs Market, Sub-Segmentation Of Pre-Mixed, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biphasic Insulin Formulations
• Pre-Mixed Combinations Of Long-Acting And Fast-Acting Insulins
• 6.9. Global Insulin Drugs Market, Sub-Segmentation Of Intermediate And Short-Acting Insulins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin NPH (Neutral Protamine Hagedorn)
• Regular Insulin (Short-Acting)

7. Insulin Drugs Market Regional And Country Analysis

• 7.1. Global Insulin Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Insulin Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Insulin Drugs Market

• 8.1. Asia-Pacific Insulin Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Insulin Drugs Market

• 9.1. China Insulin Drugs Market Overview
• 9.2. China Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Insulin Drugs Market

• 10.1. India Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Insulin Drugs Market

• 11.1. Japan Insulin Drugs Market Overview
• 11.2. Japan Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Insulin Drugs Market

• 12.1. Australia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Insulin Drugs Market

• 13.1. Indonesia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Insulin Drugs Market

• 14.1. South Korea Insulin Drugs Market Overview
• 14.2. South Korea Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Insulin Drugs Market

• 15.1. Western Europe Insulin Drugs Market Overview
• 15.2. Western Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Insulin Drugs Market

• 16.1. UK Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Insulin Drugs Market

• 17.1. Germany Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Insulin Drugs Market

• 18.1. France Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Insulin Drugs Market

• 19.1. Italy Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Insulin Drugs Market

• 20.1. Spain Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Insulin Drugs Market

• 21.1. Eastern Europe Insulin Drugs Market Overview
• 21.2. Eastern Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Insulin Drugs Market

• 22.1. Russia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Insulin Drugs Market

• 23.1. North America Insulin Drugs Market Overview
• 23.2. North America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Insulin Drugs Market

• 24.1. USA Insulin Drugs Market Overview
• 24.2. USA Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Insulin Drugs Market

• 25.1. Canada Insulin Drugs Market Overview
• 25.2. Canada Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Insulin Drugs Market

• 26.1. South America Insulin Drugs Market Overview
• 26.2. South America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Insulin Drugs Market

• 27.1. Brazil Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Insulin Drugs Market

• 28.1. Middle East Insulin Drugs Market Overview
• 28.2. Middle East Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Insulin Drugs Market

• 29.1. Africa Insulin Drugs Market Overview
• 29.2. Africa Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Insulin Drugs Market, Segmentation By Drug Clasification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Insulin Drugs Market Competitive Landscape And Company Profiles

• 30.1. Insulin Drugs Market Competitive Landscape
• 30.2. Insulin Drugs Market Company Profiles
  • 30.2.1. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly And Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Biocon Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. and Gan & Lee Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

31. Insulin Drugs Market Other Major And Innovative Companies

• 31.1. Bioton
• 31.2. Wockhardt Ltd
• 31.3. Julphar
• 31.4. Tonghua Dongbao Pharmaceutical
• 31.5. AstraZeneca
• 31.6. NIPRO
• 31.7. Olympus Medical Systems
• 31.8. Hitachi Medico
• 31.9. Nihon Kohden
• 31.10. Fukuda Denshi
• 31.11. Emperra GmbH E-Health Technologies
• 31.12. DIABNEXT
• 31.13. Berlin-Chemie AG
• 31.14. Ypsomed Holding AG
• 31.15. Patients Pending Ltd

32. Global Insulin Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Insulin Drugs Market

34. Recent Developments In The Insulin Drugs Market

35. Insulin Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Insulin Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Insulin Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Insulin Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer